Kratom Laws in Alabama 2026: Schedule I Classification and What Patients Should Know

Restoration Recovery is an outpatient addiction clinic with four locations in Southeast Tennessee and North Georgia, including a Chattanooga clinic that regularly serves patients from Jackson County and surrounding areas of North Alabama. This is the current-to-2026 read on Alabama’s kratom law, the recent enforcement activity, and how patients dependent on kratom or 7-OH can access medication-assisted treatment. It is not legal advice; if you have a specific legal question about your situation, consult an Alabama attorney.

Alabama is one of the small number of U.S. states that has completely banned kratom. The ban is not new; it has been in effect since 2016 under Alabama Code § 20-2-23, the statute that lists Schedule I controlled substances under state law. What changed in 2026 is enforcement posture: in March, the Alabama Attorney General issued a statewide cease-and-desist order directed at retailers selling products containing mitragynine or 7-hydroxymitragynine, reminding the industry and the public that the ban is active, enforceable, and being enforced.

As of July 2026, Alabama joins Arkansas, Indiana, Vermont, Wisconsin, Louisiana, Connecticut, and Tennessee (banned July 1, 2026) as states with full kratom bans. The regulatory posture elsewhere varies, with Georgia and most other states maintaining regulated-legal or unrestricted frameworks. For details on neighboring states, see our companion articles on Tennessee kratom law and Georgia kratom law.

The 2016 ban: Alabama Code § 20-2-23

In 2016, the Alabama legislature added mitragynine and 7-hydroxymitragynine (also called 7-OH), the two primary active alkaloids in kratom, to the state’s list of Schedule I controlled substances under Alabama Code § 20-2-23. Schedule I classification under state law carries the same general meaning it does federally: the substance is deemed to have a high potential for abuse and no currently accepted medical use in Alabama, and possession, manufacture, sale, and distribution are prohibited.

What the ban covers

The Alabama ban covers mitragynine and 7-hydroxymitragynine in any form. That includes raw kratom leaf, crushed kratom powder, kratom capsules, kratom extracts and tinctures, concentrated 7-OH tablets and shots, drink mixes, gummies, and any other product containing either alkaloid. Products sold under brand names that do not clearly disclose kratom content on the label are still subject to the ban if they contain the alkaloids; the Alabama Attorney General’s March 2026 enforcement action emphasized this point, noting that consumers could inadvertently possess a Schedule I controlled substance because of incomplete labeling.

Why Alabama acted when it did

Alabama was one of the first states to schedule kratom. At the time of the 2016 statute, federal authorities were considering scheduling action that was later withdrawn, and several other state legislatures were evaluating similar measures. Alabama’s framework predated the “Kratom Consumer Protection Act” regulate-and-age-gate approach that states like Georgia, Utah, and Nevada later adopted; Alabama went with prohibition before the regulatory-framework alternative became the more common legislative response.

The March 2026 Attorney General enforcement action

On March 25, 2026, the Alabama Attorney General’s office issued a statewide cease-and-desist order directed at businesses possessing or selling products containing mitragynine or 7-hydroxymitragynine. The order was paired with a public statement reminding retailers and consumers that these substances remain Schedule I under state law. Here is how the ban moved from a 2016 statute to a 2026 enforcement wave.

What the order covers

The cease-and-desist targeted several consumer-product lines marketed at gas stations, smoke shops, and similar retail channels. The Attorney General’s office flagged that some of these products were marketed under brand names that did not explicitly disclose kratom content, which raised deceptive-trade-practices concerns on top of the underlying Schedule I violation. The legal basis cited includes Alabama Code § 20-2-23 (the Schedule I classification), § 20-2-93 (seizure and forfeiture of controlled substances and associated assets), and § 8-19-1 (the Alabama Deceptive Trade Practices Act).

The Attorney General’s stated posture

The Attorney General’s office stated publicly: “Alabama will not be a marketplace for dangerous, illegal substances regardless of what they are called or how they are packaged.” Businesses with compliance questions were directed to CeaseAndDesist@AlabamaAG.gov. The practical effect of the enforcement action is to make it significantly more difficult for retailers to keep kratom-containing products on Alabama shelves, and to put consumers on notice that products previously sold under unclear labeling remain subject to the underlying prohibition.

Criminal and civil penalties in Alabama

Because kratom is a Schedule I controlled substance under Alabama law, the penalties are those that apply to possession, manufacture, and distribution of any Schedule I substance under the state’s drug statutes.

Alabama’s enforcement activity has intensified in 2026 but has varied over the years since the 2016 ban. The recent Attorney General action signals that enforcement is active at the state level; local law-enforcement posture varies by jurisdiction. Anyone with specific questions about legal exposure should consult an Alabama criminal-defense attorney licensed in the relevant county.

Federal 7-OH scheduling is on a separate track

State law is not the only regulatory story. At the federal level, kratom itself is not currently scheduled, but the status of concentrated 7-hydroxymitragynine is in motion. Three federal steps have built the case around concentrated 7-OH:

• January 22, 2025: DEA designated kratom and 7-hydroxymitragynine (7-OH) as Drugs of Concern — a signal of potential abuse without scheduling.
• July 15, 2025: FDA issued warning letters to seven companies marketing 7-OH products.
• July 29, 2025: FDA formally recommended to the DEA that concentrated 7-OH products be scheduled as Schedule I under the Controlled Substances Act. The recommendation targets concentrates specifically — tablets, gummies, drink mixes, and shots — not natural whole-leaf kratom.

The DEA is reviewing the FDA recommendation through its standard rulemaking process, which includes a public-comment period before any final action. Timing is uncertain; federal scheduling decisions often take months to years. If the DEA follows the FDA recommendation, concentrated 7-OH products become federally illegal to manufacture, sell, or possess nationwide. For Alabama residents, this changes little in practice because the state ban already covers both mitragynine and 7-OH; for residents of other states where kratom remains legal, it would mark a significant shift. For the full federal picture, see our Is 7-OH Banned Yet? federal tracker, and our companion explainer on 7-OH versus whole-leaf kratom covers the pharmacology and regulatory distinction in more depth.

What this means for Alabama residents with kratom or 7-OH dependence

If you are reading this because you are trying to stop using kratom or 7-OH, or you are worried about someone who is, this is the part that matters. Alabama’s classification of kratom as a Schedule I substance does not change any of the following:

• Medication-assisted treatment is fully legal and available to Alabama residents. Suboxone, Sublocade, and Brixadi are FDA-approved buprenorphine medications for opioid use disorder; they are prescribed every day across the United States, including to patients with kratom dependence, and their legal status is separate from kratom’s legal status.
• Insurance coverage does not change. Commercial insurance plans, Medicare, and Tricare cover medication-assisted treatment for opioid use disorder (including kratom dependence) regardless of where you live. Alabama Medicaid coverage of out-of-state outpatient treatment varies by program; the clinic intake team can verify specifics on the first call.
• Confidentiality protections remain the same. Federal 42 CFR Part 2 regulations protect the confidentiality of substance-use-disorder treatment records regardless of the substance involved or state residency.
• Seeking treatment is not a criminal risk. Patients who present for outpatient medication-assisted treatment are not subject to law-enforcement reporting based on their use history. Intake assessments are protected health information.

Why buprenorphine works for kratom dependence

Kratom’s primary active alkaloids, mitragynine and 7-hydroxymitragynine, bind to the same mu-opioid receptors that classical opioids (including fentanyl, heroin, and prescription painkillers) act on. Although kratom is not a classical opioid, the receptor activity means that the same medication-assisted treatment protocol used for opioid use disorder is clinically effective for kratom dependence. Buprenorphine, the active medication in Suboxone, Sublocade, and Brixadi, is a partial opioid agonist that relieves kratom withdrawal, suppresses craving, and provides a stable transition over weeks rather than days. For a direct comparison of buprenorphine formulations, see our Sublocade vs. Daily Suboxone decision-support page.

Treatment access from Alabama

Restoration Recovery’s Chattanooga, Tennessee clinic is located approximately 30 to 60 minutes from most of Jackson County, Alabama, including Scottsboro, Stevenson, Bridgeport, and the northeastern corner of the state. The clinic routinely serves patients from this area and is often the closest outpatient MAT option for North Alabama residents. For those further west in Alabama, other outpatient clinics across the state line in Tennessee or Georgia may be more practical. Federal law does not restrict outpatient MAT to in-state residents; any outpatient buprenorphine prescriber can legally treat patients from any state, subject to the prescriber’s individual practice scope and insurance-network limits.

What the first visit looks like

The intake process at Restoration Recovery is consistent across substances: a DSM-5 assessment to confirm substance use disorder criteria, a COWS (Clinical Opiate Withdrawal Scale) score to identify your current withdrawal state, a counseling session to set initial goals and understand your context, and a visit with a prescribing physician who chooses and doses the appropriate medication. Most patients leave the first visit with a Suboxone induction started. Sublocade and Brixadi injections require a stabilization period on daily Suboxone before the injection can be given.

Common questions Alabama patients ask

Where to check current status

For the most current Alabama legal status and enforcement activity, the Alabama Attorney General’s office press releases at alabamaag.gov are the authoritative source, along with the Alabama Legislature’s bill-tracking system at alison.legislature.state.al.us. For the federal 7-OH picture, FDA press releases and DEA announcements in the Federal Register are the authoritative sources. We update this article when Alabama or federal status changes meaningfully.

This article is published for patient information only. It is not legal advice and it is not medical advice for any individual situation. If you have a specific legal question about your situation, consult an Alabama attorney licensed in your jurisdiction.

If you are ready to stop

Alabama’s kratom ban has been in effect for almost a decade, but for many people the ban is not what prompts a decision about treatment. The decision usually comes from something more immediate: a health scare, pressure from someone close to you, or a daily dose that keeps climbing and is getting harder to manage. Whatever the reason, the clinical reality is stable. Buprenorphine-based MAT works, same-week appointments are available at our Chattanooga clinic for Alabama patients, and most insurance plans cover treatment. Call 423-498-2000 or book a callback when you are ready.

Related reading